| Schedule of financial data for the one reportable segment |
| | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Research and development: | | | | | | | | | | | | | Phase 2 study in WM | | $ | 1,134,000 | | $ | 495,000 | | $ | 1,579,000 | | $ | 1,128,000 | Phase 1 study in pediatric tumors | | | 427,000 | | | 243,000 | | | 657,000 | | | 976,000 | Phase 1 study in triple-negative breast cancer | | | 790,000 | | | — | | | 1,114,000 | | | — | Phase 3 study in WM | | | 153,000 | | | — | | | 172,000 | | | — | Manufacturing and related costs | | | 1,278,000 | | | 871,000 | | | 2,522,000 | | | 1,580,000 | Pre-clinical projects cost | | | 74,000 | | | 145,000 | | | 135,000 | | | 652,000 | General research and development costs | | | 701,000 | | | 636,000 | | | 1,386,000 | | | 1,481,000 | General and administrative | | | 2,639,000 | | | 3,648,000 | | | 5,425,000 | | | 6,622,000 | Other segment items | | | (265,000) | | | (590,000) | | | (405,000) | | | (387,000) | Segment and consolidated net loss | | $ | 6,931,000 | | $ | 5,448,000 | | $ | 12,585,000 | | $ | 12,052,000 |
|